Literature DB >> 10787466

Adverse effects of corticosteroids on the cardiovascular system.

D E Sholter1, P W Armstrong.   

Abstract

OBJECTIVE: To review the potential adverse effects of glucocorticoid therapy on the cardiovascular system and to provide insight into the mechanisms of these effects. DATA SOURCES: Case reports and studies demonstrating adverse effects of glucocorticoid therapy on the cardiovascular system were examined from a MEDLINE search. Animal data and in vitro studies were identified to provide insight on the mechanisms of these effects. DATA SYNTHESIS: Undesirable effects identified were dyslipidemia, hypertension and left ventricular free wall rupture after myocardial infarction. Elevations of total plasma cholesterol, triglycerides, low density lipoprotein cholesterol and high density lipoprotein cholesterol are often reported. The elevation of various lipid subfractions is likely mediated by increased plasma insulin levels, impaired lipid catabolism and increased lipid production in the liver. Hypertension was shown to be more prevalent in patients treated with high doses of glucocorticoid. The mechanisms are complex, but final pathways include increased systemic vascular resistance, increased extracellular volume and increased cardiac contractility. Glucocorticoids were demonstrated to increase the incidence of left ventricular free wall rupture by delaying myocardial scar formation in the postmyocardial infarction period.
CONCLUSIONS: The major adverse effects of glucocorticoids on the cardiovascular system include dyslipidemia and hypertension. These effects may predispose treated patients to coronary artery disease if high doses and prolonged courses are used. Accordingly, corticosteroids should be employed judiciously in patients with other risk factors for cardiovascular disease, and attention should be paid to risk modification. Low dose and alternate day therapy may reduce the incidence of complications in corticosteroid therapy. The mechanisms of these adverse effects are complex and have not yet been fully explained.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10787466

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  65 in total

1.  Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide.

Authors:  Jeffrey G Stark; Sybille Werner; Susanne Homrighausen; Yufei Tang; Michael Krieg; Hartmut Derendorf; Helmut Moellmann; Guenther Hochhaus
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04-22       Impact factor: 2.745

2.  Glucocorticoid treatment and cardiovascular disease.

Authors:  M K C Ng; D S Celermajer
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

Review 3.  Drug-induced endocrine and metabolic disorders.

Authors:  Ronald C W Ma; Alice P S Kong; Norman Chan; Peter C Y Tong; Juliana C N Chan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  Roflumilast: a green signal is yet to come.

Authors:  Nazir Lone; Yuji Oba
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

5.  Severe hypercholesterolemia associated with decreased hepatic triglyceride lipase activity and pseudohyponatremia in patients after allogeneic stem cell transplantation.

Authors:  Yoshihiro Inamoto; Tamio Teramoto; Koji Shirai; Hideko Tsukamoto; Takaomi Sanda; Koichi Miyamura; Ikuo Yamamori; Noriyuki Hirabayashi; Yoshihisa Kodera
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

6.  Patterns and predictors of medication adherence to lipid-lowering therapy in children aged 8 to 20 years.

Authors:  Nina R Joyce; Gregory A Wellenius; Charles B Eaton; Amal N Trivedi; Justin P Zachariah
Journal:  J Clin Lipidol       Date:  2016-03-10       Impact factor: 4.766

Review 7.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

8.  Role of BCL2-associated athanogene 1 in differential sensitivity of human endothelial cells to glucocorticoids.

Authors:  Eugenia Mata-Greenwood; John M Stewart; Robin H Steinhorn; William J Pearce
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-03-14       Impact factor: 8.311

9.  Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.

Authors:  Zurab Nadareishvili; Kaleb Michaud; John M Hallenbeck; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2008-08-15

10.  Drugs to Treat Systemic Lupus Erythematosus: Relationship between Current Use and Cardiovascular Risk Factors.

Authors:  Young Hee Rho; Annette Oeser; Cecilia P Chung; Jason D Morrow; C Michael Stein
Journal:  Arch Drug Inf       Date:  2008-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.